Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT95SOA)

DTT Name Interferon alpha (IFNA)
Synonyms IFN-A
Gene Name IFNA
DTT Type
Successful target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T45598
Function Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Regulation of autophagy (hsa04140 )
PI3K-Akt signaling pathway (hsa04151 )
Toll-like receptor signaling pathway (hsa04620 )
RIG-I-like receptor signaling pathway (hsa04622 )
Cytosolic DNA-sensing pathway (hsa04623 )
Jak-STAT signaling pathway (hsa04630 )
Natural killer cell mediated cytotoxicity (hsa04650 )
Tuberculosis (hsa05152 )
Hepatitis C (hsa05160 )
Hepatitis B (hsa05161 )
Measles (hsa05162 )
Influenza A (hsa05164 )
Herpes simplex infection (hsa05168 )
Autoimmune thyroid disease (hsa05320 )
Reactome Pathway
Regulation of IFNA signaling (R-HSA-912694 )
TRAF6 mediated IRF7 activation (R-HSA-933541 )
Factors involved in megakaryocyte development and platelet production (R-HSA-983231 )
Interferon alpha/beta signaling (R-HSA-909733 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alfaferone DMCKPUR Hairy cell leukaemia 2A82.2 Approved [2]
Interferon alfa-n3 DMTZNQ9 Human immunodeficiency virus infection 1C62 Approved [1]
------------------------------------------------------------------------------------
9 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
P1101 DM5DRMY Polycythemia vera 2A20.4 Phase 3 [3]
Human interferon alpha oral DMKQ3MC Hepatitis C virus infection 1E51.1 Phase 2 [4]
IFN-alpha DM4H8EZ Hepatitis C virus infection 1E51.1 Phase 2 [5]
Interferon-alpha lozenge DM8YF01 Behcet disease 4A62 Phase 2 [6]
Rontalizumab DMBJN19 Systemic lupus erythematosus 4A40.0 Phase 2 [7]
IFN alpha kinoid DMLEVFW Human immunodeficiency virus infection 1C62 Phase 1/2 [8]
Ad-IFN-alpha DMM45P9 Bladder cancer 2C94 Phase 1 [9]
AGS-009 DMU21JF Systemic lupus erythematosus 4A40.0 Phase 1 [10]
NG-641 DMITVHM Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Clinical Trial Drug(s)
3 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PEG-Infergen DMGD20T Hepatitis virus infection 1E50-1E51 Discontinued in Phase 2 [12]
Gene therapy, IFN-alpha DMVAM18 Head and neck cancer 2D42 Terminated [9]
R-7025 DMLAIZG Hepatitis B virus infection 1E51.0 Terminated [13]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Hemispherx Biopharma.
2 Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
3 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
4 Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
5 WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
6 Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
7 Clinical pipeline report, company report or official report of Genentech (2011).
8 Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
9 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
10 Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
11 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
12 Patent CN102245599 B.
13 WO patent application no. 2013,0667,53, Compositions useful for the treatment of viral diseases.